Evaluation of the Braak staging of brain pathology with 1 H-MRS in patients with Parkinson’s disease

Cao, Hongmei; Shi, Jie; Cao, Bingqing; Bei, Kang; Zhang, Ming; Qu, Qing

doi:10.1016/j.neulet.2017.08.050

Cited by 13 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, corresponding to the fact that the basal ganglia, which has been reported to be involved in PD pathological processes in previous MRS studies (22, 23, 31–36), are located in the temporal and frontal lobar atlas regions used in this study, we found that most metabolic changes occurred in temporal lobe, while the frontal NAA changes correlated significantly to MDS-UPDRS score describing clinical symptoms. Previous studies have reported a significant correlation of NAA/tCr to clinical symptoms (11, 31, 33, 34). However, this study found that tCr was also altered in PD, which is consistent with reduced concentrations of phosphates in the striatum and midbrain that has been interpreted as early mitochondrial dysfunction in PD patients (37).…”

Section: Discussionmentioning

confidence: 85%

“…Further validation of this study is also needed in a larger sample of patients together with a more comprehensive clinical phenotyping of PD subtypes (61–63). The identification of PD related metabolic changes in the white matter, cortical gray matter and basal ganglia may help to understand the metabolic processes during disease progression and spreading of neurodegenerative pathology in the brain (33, 64).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging

et al. 2019

View full text Add to dashboard Cite

Objective: To estimate alterations in neurometabolic profile of patients with early stage Parkinson's disease (PD) by using a short echo-time whole brain magnetic resonance spectroscopic imaging (wbMRSI) as possible biomarker for early diagnosis and monitoring of PD. Methods: 20 PD patients in early stage (H&Y ≤ 2) without evidence of severe other diseases and 20 age and sex matched healthy controls underwent wbMRSI. In each subject brain regional concentrations of metabolites N-acetyl-aspartate (NAA), choline (Cho), total creatine (tCr), glutamine (Gln), glutamate (Glu), and myo-inositol (mIns) were obtained in atlas-defined lobar structures including subcortical basal ganglia structures (the left and right frontal lobes, temporal lobes, parietal lobes, occipital lobes, and the cerebellum) and compared between patients and matched healthy controls. Clinical characteristics of the PD patients were correlated with spectroscopic findings. Results: In comparison to controls the PD patients revealed altered lobar metabolite levels in all brain lobes contralateral to dominantly affected body side, i.e., decreases of temporal NAA, Cho, and tCr, parietal NAA and tCr, and frontal as well as occipital NAA. The frontal NAA correlated negatively with the MDS-UPDRS II ( R = 22120.585, p = 0.008), MDS-UPDRS IV ( R = −0.458, p = 0.048) and total MDS-UPDRS scores ( R = −0.679, p = 0.001). Conclusion: In early PD stages metabolic alterations are evident in all contralateral brain lobes demonstrating that the neurodegenerative process affects not only local areas by dopaminergic denervation, but also the functional network within different brain regions. The wbMRSI-detectable brain metabolic alterations reveal the potential to serve as biomarkers for early PD.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Cho as a marker of both membrane catabolism and anabolism. Cao et al (Cao et al, 2017) found that Cho/Cr in SN are related to the PD severity, without mention cognitive impairment. Nie et al (Nie et al, 2013) reported that the increase in the ratio of Cho/Cr in the PCC was associated with PDMCI, and suggested that Cho/Cr ratio maybe used as the marker for the detection of PDMCI.…”

Section: B)mentioning

confidence: 99%

A Comparative study of Posterior cingulate metabolism in Patients with Mild Cognitive Impairment due to Parkinson’s Disease or to Alzheimer’s Disease

Huang

Cai

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Few comparative studies exist of metabolic brain changes in cognitive impairment among neurodegenerative illnesses. In this study, we compared posterior cingulate (PCC) metabolic abnormalities in patients with mild cognitive impairment (MCI) due to Parkinson’s disease (PD) and to Alzheimer’s disease (AD) as measured by proton magnetic resonance spectroscopy (1H-MRS). Thirty eight patients with idiopathic PD, including 20 patients with mild cognitive impairment (PDMCI), 18 patients with normal cognitive (PDN), 18 patients with probable mild cognitive impairment (ADMCI), and 25 healthy older controls (HC) underwent PCC 1H-MRS scans. Compared with controls, patients with PDMCI exhibited significantly reduced concentration of N-acetyl aspartate (NAA) and total Creatine (tCr), While patients with ADMCI exhibited significantly increased concentration of myo-inositol (Ins), and reduced NAA/Ins ratio. There was reduced concentration of NAA, Ins and tCr in PDMCI compared with ADMCI. No significant metabolic alteration was found in PDN subjects. Besides, ROC analysis revealed that the concentration of tCr could differentiate PDMCI from PDN with an AUC of 0.71, and the level of NAA/Ins ratio could differentiate subjects with MCI from normal cognitive controls with an AUC of 0.74. Patients with PDMCI and ADMCI exhibited distinct PCC metabolic 1H-MRS profiles. Findings suggest that cognitively normal PD patients with low NAA, tCr in the PCC might be at risk of preclinical PDMCI, and also the Ins and/or NAA/MI ratio in the PCC should be reconsidered as a possible biomarker of preclinical MCI in clinical practice. So, comparison of PCC 1H-MRS profiles of cognitive impairment among neurodegenerative illnesses may provide useful information for better defining the disease process and elucidate possible treatment mechanisms.

show abstract

“…Reduced N-acetyl aspartate/creatine (NAA/Cr) ratios in the SN have been observed in PD vs. controls, which were shown to correlate with disease severity ( 69 , 70 ). Lowered NAA or NAA/Cr values have also been detected in other regions, including the lentiform nucleus (LN) (comprises of putamen and globus pallidus; basic anatomy presented in Figure 2 ), temporoparietal and posterior cingulate cortex, and pre-supplementary motor area vs. controls ( 71 – 74 ).…”

Section: Structural Neuroimaging In Parkinsonian Disordersmentioning

confidence: 99%

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes

2020

View full text Add to dashboard Cite

Evaluation of the Braak staging of brain pathology with 1 H-MRS in patients with Parkinson’s disease

Cited by 13 publications

References 29 publications

Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging

Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging

A Comparative study of Posterior cingulate metabolism in Patients with Mild Cognitive Impairment due to Parkinson’s Disease or to Alzheimer’s Disease

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes

Contact Info

Product

Resources

About